Cornerstone Investment Partners LLC Invests $210,000 in MiMedx Group, Inc. (NASDAQ:MDXG)

Cornerstone Investment Partners LLC acquired a new stake in MiMedx Group, Inc. (NASDAQ:MDXG) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 21,792 shares of the company’s stock, valued at approximately $210,000.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of MiMedx Group by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock valued at $16,518,000 after purchasing an additional 44,254 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in MiMedx Group by 6.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock valued at $8,483,000 after buying an additional 92,726 shares in the last quarter. Royce & Associates LP grew its position in MiMedx Group by 5.3% in the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after acquiring an additional 48,539 shares during the last quarter. Bank of New York Mellon Corp raised its stake in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN lifted its holdings in shares of MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock worth $2,100,000 after acquiring an additional 2,737 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MDXG has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, MiMedx Group currently has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Performance

MiMedx Group stock opened at $8.10 on Wednesday. The business has a 50 day moving average of $8.68 and a 200-day moving average of $7.75. The company has a market capitalization of $1.19 billion, a P/E ratio of 14.73 and a beta of 1.94. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, equities research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.